2010 Autumn Conference
13 – 14 October, 2010 // Baltimore, Maryland, USA
Poster Awardees: |
||
Randomization Strategies for Clustered Clinical Syndromes: Effects on Statistical Power B Lebowitz, Y Wang, N Duan, CF Reynolds III, NM Simon, S Zisook, MK Shear |
||
Reconsidering the Criterion for Excluding Comorbid Substance Use Disorders from Clinical Trials for the Treatment of Depression L Davis |
||
Methodological Challenges of Demonstrating Cognitive Improvements with Broad Spectrum Agents: A Novel Approach Y Geffen, M Davidson, M Hufford, RM Gendreau, S Rao, R.Zablocki, J Kranzler |
||
Day 1 (13 October 2010) |
||
President’s Welcome | L Alphs![]() ![]() |
|
S1: MATRICS Update and Beyond |
Chairs: S Marder M Egan |
|
Introduction | S Marder![]() ![]() |
|
The MATRICS Approach to Measuring Cognition: Foundational Issues and Critical Decisions | M Green![]() |
|
Real-World Application of the MATRICS Consensus Cognitive Battery (MCCB) in Multisite Clinical Trials | R Keefe![]() ![]() |
|
Assessment of Functional Outcomes | D Velligan![]() ![]() |
|
Challenges in Drug Development for Cognitive Impairment Associated with Schizophrenia | M Egan* |
|
Cognition in Schizophrenia: New Directions in Clinical Trials at NIMH | B Cuthbert![]() |
|
Bridging the Gaps Between Animal Models, Human Neuroscience and Schizophrenia Clinical Trials: Rational Enhancement of Signal Detection | J Sweeney![]() |
|
Cognitive Remediation as a Platform for Clinical Trials of Cognitive Enhancing Drugs in Schizophrenia | A Reichenberg![]() |
|
Cognitive Assessment for Schizophrenia Clinical Trials in the Post-MATRICS Era | R Bilder![]() |
|
Standardized Approach to Clinical Trials: Risks, Benefits, and a Working Model | S Koslow![]() |
|
Exemplar Applications and Results From BRAINnet: What Are The Implications for Understanding, Modeling, Diagnosing and Treating Brain Disorders? | S Silverstein![]() |
|
Regulatory Perspective MATRICS and Beyond: US Perspective | T Laughren![]() |
|
Regulatory Perspective MATRICS and Beyond: European Perspective | K Broich![]() ![]() |
|
Panel Discussion | Chair: M Egan ![]() Panelists: K Broich T Laughren R Keefe ![]() |
|
Summary | S Marder![]() |
|
Poster Session | View All Poster Abstracts | |
Day 2 (14 October 2010) |
||
S2: Concurrent Workshops | ||
Sources And Management Of Placebo Effects In CNS Clinical Trials | A Kalali L Ereshefsky ![]() |
|
Methodological Issues for Studying Negative Symptoms of Schizophrenia | S Marder D Daniel ![]() |
|
Health Information Technology and Electronic Medical Records: What Are the Scientific and Policy Priorities for the Field of CNS Clinical Research? | J Davis R Ferziger |
|
Questionable Data: Recognition and Resolution | G Sachs J Severe ![]() ![]() ![]() |
|
Mitochondrial Systems as Targets for Development of Novel Pharmacological Interventions for CNS Disorders Session Summary |
C Bowden A Nierenberg ![]() |
|
Suicidality Assessment in Clinical Trials: Methodological and Technical Challenges | A Butler M Stewart ![]() ![]() |
|
Session 3: DSM-5: Implications for Clinical Trials | Chairs: N Schooler R Hirschfeld |
|
Introduction | N Schooler![]() |
|
Implications of DSM-5 Mood Disorders for Future Treatment Efficacy Trials | J Fawcett![]() ![]() |
|
Schizophrenia and Psychotic Disorders in DSM-5 | J Bustillo![]() |
|
Regulatory Perspectives from FDA and EMEA | M Mathis![]() K Broich ![]() |
|
Public Perspective | J McNulty![]() |
|
General Discussion | R Hirschfeld | |
Meeting Adjourns | ||
* Materials have not been released. |